Acurx Pharmaceuticals, Inc. (ACXP)
NASDAQ: ACXP · IEX Real-Time Price · USD
2.61
0.09 (3.69%)
At close: May 27, 2022 3:56 PM
2.21
-0.40 (-15.42%)
After-hours:May 27, 2022 7:30 PM EDT
Company Description
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections.
Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections.
The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae.
Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Acurx Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2017 |
| IPO Date | Jun 25, 2021 |
| Industry | Biotechnology |
| Sector | Health Care |
| Employees | 3 |
Contact Details
Address: 259 Liberty Avenue Staten Island, NY 10305 United States | |
| Phone | 917-533-1469 |
Stock Details
| Ticker Symbol | ACXP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | US Dollars |
| IPO Price | $6.00 |
| CIK Code | 1736243 |
Key Executives
| Name | Position |
|---|---|
| Robert J. DeLuccia | Co-Founder and Executive Chairman |
| David P. Luci CPA, CPA, Esq., J.D. | Corporate Secretary, Co-Founder, President, Chief Executive Officer and Director |
| Robert G. Shawah CPA | Co-Founder and Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 11, 2022 | 8-K | Current report |
| May 10, 2022 | 10-Q | Quarterly report [Sections 13 or 15(d)] |
| Apr 25, 2022 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 25, 2022 | DEF 14A | Other definitive proxy statements |
| Mar 17, 2022 | 8-K | Current report |
| Mar 16, 2022 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 16, 2022 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] |
| Nov 24, 2021 | 4 | Statement of changes in beneficial ownership of securities |
| Nov 22, 2021 | 4 | Statement of changes in beneficial ownership of securities |
| Nov 22, 2021 | 4 | Statement of changes in beneficial ownership of securities |
| View All SEC Filings | ||